,outcome,arm 1,arm 2
0,intervention,Capecitabine/docetaxel,docetaxel
0,overall survival,14.5,11.5 months
0,time to disease progression ( TTP ),6.1,4.2 months
0,objective tumor response rate,42 %,30 %
